CN115379825A - 用rodatristat治疗肺动脉高压的剂量和方法 - Google Patents

用rodatristat治疗肺动脉高压的剂量和方法 Download PDF

Info

Publication number
CN115379825A
CN115379825A CN202180021555.2A CN202180021555A CN115379825A CN 115379825 A CN115379825 A CN 115379825A CN 202180021555 A CN202180021555 A CN 202180021555A CN 115379825 A CN115379825 A CN 115379825A
Authority
CN
China
Prior art keywords
rodatristat
ethyl
compound
daily dose
rvt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202180021555.2A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·A·沃林
米歇尔·帕拉西奥斯
凯特琳·雷格哈德·克雷泽
比尔·西蒙兹
丹尼尔·帕特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altawante Science
Original Assignee
Altawante Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altawante Science filed Critical Altawante Science
Publication of CN115379825A publication Critical patent/CN115379825A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180021555.2A 2020-01-31 2021-01-29 用rodatristat治疗肺动脉高压的剂量和方法 Withdrawn CN115379825A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968651P 2020-01-31 2020-01-31
US62/968,651 2020-01-31
PCT/IB2021/000046 WO2021152398A1 (en) 2020-01-31 2021-01-29 Dosages and methods for treating pulmonary arterial hypertension with rodatristat

Publications (1)

Publication Number Publication Date
CN115379825A true CN115379825A (zh) 2022-11-22

Family

ID=75143674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021555.2A Withdrawn CN115379825A (zh) 2020-01-31 2021-01-29 用rodatristat治疗肺动脉高压的剂量和方法

Country Status (9)

Country Link
US (1) US20230074252A1 (enExample)
EP (1) EP4096633A1 (enExample)
JP (1) JP2023512025A (enExample)
KR (1) KR20220156813A (enExample)
CN (1) CN115379825A (enExample)
AU (1) AU2021212355A1 (enExample)
CA (1) CA3165432A1 (enExample)
MX (1) MX2022009254A (enExample)
WO (1) WO2021152398A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210105343A (ko) 2018-11-16 2021-08-26 알타반트 사이언시스 게엠베하 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) * 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제

Also Published As

Publication number Publication date
CA3165432A1 (en) 2021-08-05
EP4096633A1 (en) 2022-12-07
US20230074252A1 (en) 2023-03-09
MX2022009254A (es) 2022-09-07
KR20220156813A (ko) 2022-11-28
WO2021152398A1 (en) 2021-08-05
AU2021212355A1 (en) 2022-08-18
JP2023512025A (ja) 2023-03-23

Similar Documents

Publication Publication Date Title
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
US10561659B2 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
JP2008510830A (ja) ホスホジエステラーゼ５阻害剤（ｐｄｅ５）と併用するエンドセリンａ受容体（ｅｔａ）アンタゴニストおよびその使用
US20120157472A1 (en) Method for treating colorectal cancer
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
US9907795B2 (en) Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
US20210290651A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
US20080039428A1 (en) Antiretroviral combination therapy
AU2021212355A1 (en) Dosages and methods for treating pulmonary arterial hypertension with rodatristat
WO2024091624A1 (en) Pharmaceutical formulations and uses thereof
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
WO2018005328A1 (en) Deuterated bictegravir
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
HK40079142A (en) Dosages and methods for treating pulmonary arterial hypertension with rodatristat
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
US12357577B1 (en) Pharmaceutical formulations and uses thereof
US20260000618A1 (en) Pharmaceutical formulations and uses thereof
US20250213550A1 (en) Compounds and methods for treating inflammatory bowel disease
Carbo Tutusaus et al. American Chemical Society-251st National Meeting and Exposition. San Diego, California, USA-March 13-17, 2016
WO2024102778A1 (en) Pyrrolopyrimidine compositions for treatment of itk mediated conditions
CA3268765A1 (en) Pharmaceutical formulations and uses thereof
Gras Avapritinib. PDGFR-alpha and KIT mutant inhibitor, Treatment of gastrointestinal stromal tumor, Treatment of systemic mastocytosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079142

Country of ref document: HK

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20221122